FEB 15, 2018 09:00 AM PST

What is a CAR-T cell therapy?


Most people must have heard revolutionary cancer therapy called CAR-T cell therapy, a kind of cancer immunotherapy. It has changed the landscape of cancer therapy and has the potential of curing some of the chemotherapy refractory blood cancer such as acute lymphoblastic leukemia (ALL).
Cancer immunotherapy is not a very new science, but it is the culmination of cumulative knowledge gained through countless experiments in immunology and cancer. In 1893, William Coley's observed reduction in tumor size upon injection of streptococcus bacteria. Giving BCG vaccine in early stage of bladder cancer is a form of oldest cancer immunotherapy which is still used in clinical practice.
T cells are the type of a white blood cell which plays an essential role in mounting an appropriate immune response to either diseased cells (virus-infected or cancer cells) or foreign pathogens. Cytotoxic T cells are central in killing cancerous cells. They recognize cancer cells through a particular receptor called T cell receptor (TCR) which binds to the novel antigen expressed only on cancer cells and thereby killing them. However, cytotoxic T cell which can recognize unique tumor antigen is scarce in number, or sometimes tumor itself create microenvironment to decrease their frequency around the tumor microenvironment. One way to overcome this challenge is to engineer T cells ex-vivo isolated from either blood of the patient or healthy individual. In this method, T cells are engineered to produce a single chain variable fragment of an antibody (chimeric antigen receptor; CAR) which recognizes unique antigen only expressed onto tumor cells, e.g., CD19 in case of ALL. They are expended in large number ex-vivo and injected into the patient, where further proliferation produces more engineered T cells specific to tumor cells. Expended CAR-T cells lead to complete killing of all tumor cells without harming healthy normal cells, unlike conventional cancer treatment where most of the side effects come from the killing of healthy cells. However, there are some challenges associated with CAR-T cell therapy such as cytokine storm and expensive nature of its production. Moreover, they are not currently suitable for solid tumors which constitute the majority of cancer found among the population.
FDA has recently approved two CAR-T cell therapy based on CD19 chimeric antigen receptor to treat ALL and diffuse large B cell lymphoma.
About the Author
  • Biological research scientist by profession with passion to write about science in general.
You May Also Like
NOV 12, 2018
Plants & Animals
NOV 12, 2018
Steaks Aren't the Only Things We Get From Cows
It’s no secret that cows are routinely slaughtered for beef, but what if we told you that only about 60% of the cow gets harvested for food? Fret not...
NOV 22, 2018
Chemistry & Physics
NOV 22, 2018
The Hottest Spice That You Probably Don't Want to Savor
Transient Receptor Potential Vanilloid 1 cation channel, or TRPV1, plays an important role in the human body in sensing heat and pain.  Coincidentally...
NOV 26, 2018
Space & Astronomy
NOV 26, 2018
Here's What An ISS Resupply Launch Looks Like From Space
Filmed rocket launches have become the norm here on Earth, but most cameras are situated at ground level, either shooting the takeoff from the launchpad or...
NOV 27, 2018
Space & Astronomy
NOV 27, 2018
Here's What Makes Mars So Challenging to Land On
Humankind has sent spacecraft to a plethora of worlds in our solar system, including asteroids, comets, moons, and planets. Of all, Mars has consistently p...
DEC 06, 2018
Videos
DEC 06, 2018
Stopping the Spread of Antibiotic Resistant Bacteria
This informative video from the Centers for Disease Control and Prevention outlines the problem of antibiotic resistance....
DEC 07, 2018
Videos
DEC 07, 2018
The Influence of Genetics on our Future
In recent decades, advances in genetic technologies have changed our world in many different ways....
Loading Comments...